@article {1403,
	title = {Generic antiretroviral efficacy in AIDS-associated Kaposi{\textquoteright}s sarcoma in sub-Saharan Africa.},
	journal = {AIDS (London, England)},
	volume = {19},
	year = {2005},
	month = {2005 Mar 4},
	pages = {441-3},
	abstract = {Generic antiretroviral drugs are pivotal in the implementation of WHO{\textquoteright}s {\textquoteright}3 by 5{\textquoteright} programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi{\textquoteright}s sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74\% achieved an undetectable viral load of < 50 copies/ml, 86\% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.},
	keywords = {Acquired Immunodeficiency Syndrome, Africa South of the Sahara, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Developing Countries, Drugs, Generic, Humans, Sarcoma, Kaposi, Treatment Outcome, Viral Load},
	issn = {0269-9370},
	doi = {10.3109/00952990.2011.568081},
	author = {Mosam, Anisa and Cassol, Edana and Page, Taryn and Bodasing, Uvani and Cassol, Sharon and Dawood, Halima and Friedland, Gerald H and Scadden, David T and Aboobaker, Jamila and Jordaan, Jacobus P and Lalloo, Umesh G and Esterhuizen, Tonya M and Coovadia, Hoosen M}
}
